15.05
price down icon0.59%   -0.09
after-market Handel nachbörslich: 15.05
loading
Schlusskurs vom Vortag:
$15.14
Offen:
$15.12
24-Stunden-Volumen:
935.36K
Relative Volume:
0.55
Marktkapitalisierung:
$47.43B
Einnahmen:
$30.25B
Nettoeinkommen (Verlust:
$1.37B
KGV:
35.35
EPS:
0.4257
Netto-Cashflow:
$5.08B
1W Leistung:
-0.92%
1M Leistung:
+4.95%
6M Leistung:
+3.51%
1J Leistung:
+8.35%
1-Tages-Spanne:
Value
$14.89
$15.12
1-Wochen-Bereich:
Value
$14.89
$15.17
52-Wochen-Spanne:
Value
$12.57
$15.30

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Name
Firmenname
Takeda Pharmaceutical Co Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
0
Name
Twitter
@takedapharma
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
TAK's Discussions on Twitter

Vergleichen Sie TAK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.05 47.43B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
163.11 73.07B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.24 45.72B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.08 17.28B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
131.81 14.03B 612.78M -86.37M -62.91M -0.87

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-03-16 Hochstufung BofA Securities Neutral → Buy
2022-07-19 Hochstufung Cowen Market Perform → Outperform
2021-10-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-04-19 Herabstufung JP Morgan Overweight → Neutral
2019-11-01 Eingeleitet Cowen Market Perform
2019-08-15 Herabstufung Daiwa Securities Outperform → Neutral
Alle ansehen

Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten

pulisher
Mar 26, 2025

[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.

Mar 26, 2025
pulisher
Mar 14, 2025

PD Stock on the Rise: A Promising Investment - The InvestChronicle

Mar 14, 2025
pulisher
Mar 14, 2025

TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Mar 14, 2025
pulisher
Mar 14, 2025

China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle

Mar 14, 2025
pulisher
Mar 14, 2025

Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets

Mar 14, 2025
pulisher
Mar 13, 2025

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha

Mar 13, 2025
pulisher
Mar 10, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Mar 10, 2025
pulisher
Mar 06, 2025

Charles Schwab Trying To Close In On Key Technical Measure - Inkl

Mar 06, 2025
pulisher
Mar 04, 2025

Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle

Mar 04, 2025
pulisher
Mar 04, 2025

Takeda Pharmaceutical ADR Trying To Close In On Key Technical Measure - Inkl

Mar 04, 2025
pulisher
Feb 18, 2025

XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN

Feb 18, 2025
pulisher
Feb 17, 2025

TAK vs. DSNKY: Which Stock Is the Better Value Option? - Nasdaq

Feb 17, 2025
pulisher
Feb 15, 2025

Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN

Feb 15, 2025
pulisher
Feb 15, 2025

Vyvanse Leaks: Beyond The Headlines - Truth or Fiction

Feb 15, 2025
pulisher
Feb 14, 2025

IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR

Feb 14, 2025
pulisher
Feb 13, 2025

IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, - openPR

Feb 13, 2025
pulisher
Feb 10, 2025

Procter & Gamble Co (PG) expanding its growth trajectory ahead - SETE News

Feb 10, 2025
pulisher
Feb 10, 2025

Prepare Yourself for Liftoff: AMKOR Technology Inc (AMKR) - SETE News

Feb 10, 2025
pulisher
Feb 07, 2025

Takeda Pharmaceutical Co ADR [TAK] President, Plasma-Derived Ther makes an insider purchase of 19,073 shares worth 0.28 million. – Knox Daily - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Advanced Drainage Systems Inc [WMS] Records 50-Day SMA of $122.78 - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

GFL Shares Experience Surge in Value - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

UBS Group AG [UBS] Shares Rise 2.39 % on Thursday - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Takeda Pharmaceutical Co ADR (TAK)’s stock price range in the last year - US Post News

Feb 07, 2025
pulisher
Feb 05, 2025

Inmode Ltd (INMD) Stock Price and Analyst Predictions - The News Heater

Feb 05, 2025
pulisher
Feb 03, 2025

Recent Insider Activity Could Benefit Wabash National Corp (WNC) - Knox Daily

Feb 03, 2025
pulisher
Feb 03, 2025

Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - Knox Daily

Feb 03, 2025
pulisher
Jan 30, 2025

Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition - MSN

Jan 30, 2025
pulisher
Jan 27, 2025

Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World - Dealbreaker

Jan 27, 2025
pulisher
Jan 21, 2025

Keros Therapeutics seals $200M deal with Takeda - Investing.com

Jan 21, 2025
pulisher
Jan 15, 2025

Japan’s Takeda launches innovation centre in Bengaluru; to hire 750 in 2025 - Deccan Herald

Jan 15, 2025
pulisher
Jan 14, 2025

Weekly Upgrades and Downgrades - InvestorPlace

Jan 14, 2025
pulisher
Jan 02, 2025

Amgen stock price formed a death cross: will it rebound in 2025? - MSN

Jan 02, 2025
pulisher
Dec 30, 2024

Takeda-backed Ascentage Pharma files for $100M IPO (IPO:NYSEARCA) - Seeking Alpha

Dec 30, 2024

Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_specialty_generic HLN
$10.24
price up icon 1.19%
drug_manufacturers_specialty_generic ZTS
$163.11
price down icon 1.16%
$15.08
price down icon 2.65%
$131.81
price up icon 0.05%
$113.16
price down icon 0.74%
Kapitalisierung:     |  Volumen (24h):